ARTICLE | Clinical News
Tyrima: Phase I data
March 19, 2007 7:00 AM UTC
In a single-dose, dose-escalation, placebo-controlled, U.S. Phase I trial in 41 healthy volunteers, Tyrima was well tolerated with no significant adverse events even at the highest dose of 120 mg. Pla...